AASLD 2015

AASLD 2015

Naltrexone/bupropion Improves Liver Enzymes in Obese, Overweight

Treatment with extended release naltrexone/bupropion (NB) for weight loss significantly improved and normalized serum ALT levels in obese and overweight individuals at high risk for non-alcoholic fatty liver disease (NAFLD) with elevated liver enzymes, reported Allison Winokur, PhD, from Takeda Pharmaceuticals U.S.A., Inc., Deerfield, IL, at The Liver Meeting® 2015.

PegIFN alfa-2b Non-Inferior to PegIFN alfa-2a in CHB

Peginterferon alfa-2b (Pegberon) demonstrates non-inferior efficacy to peginterferon alfa-2a (PEG IFNα-2a) for the treatment of Chinese HBeAg-positive chronic hepatitis B (CHB) patients, reported Gui-Qiang Wang, MD, PhD, from Peking University First Hospital, Beijing, China, at The Liver Meeting® 2015.

For HBV Patients With Low Viral Load, Combo Therapy Better Than None

Combination treatment with peginterferon alfa-2a (peg-IFN) and adefovir or tenofovir for 48 weeks results in a loss and greater decline in HBsAg compared to no treatment in chronic hepatitis B (CHB) patients with a low viral load (LVL), reported Annikki de Niet, MD, from Academic Medical Center, Amsterdam, Netherlands, at The Liver Meeting® 2015.

Treating Hepatitis C Virus: How the Standard of Care is Evolving

RA, Psoriasis Meds May Up Risk of Hep B Flares

Biologic agents are associated with “significantly higher” risk of hepatitis B virus (HBV) flares than non-biologic disease-modifying antirheumatic drugs (nbDMARDs) among patients with rheumatoid arthritis (RA) or psoriasis, according to a study reported at The Liver Meeting® 2015.